品牌:JinPan | 货号:IP1280-25mg
产品简介
CAS | 58-58-2 |
中文名称 | 嘌呤霉素二盐酸盐 |
英文名称 | Puromycin dihydrochloride |
别名 | 二氢氯化嘌呤毒素;Stillomycin |
纯度 | HPLC≥98% |
单位 | 支 |
分子式 | C22H31Cl2N7O5 |
分子量 | 544.43 |
外观(性状) | White to light yellow Solid |
储存条件 | Powder : -20℃, 2 years;In solvent(母液): -20℃, 1 month; -80℃, 6 months |
溶解性 | Soluble in Water |
EC | EINECS 200-387-8 |
MDL | MFCD00012691 |
SMILES | OC[C@@H]1[C@@H](NC([C@@H](N)CC2=CC=C(OC)C=C2)=O)[C@H]([C@H](N3C=NC4=C3N=CN=C4N(C)C)O1)O.[H]Cl.[H]Cl |
描述 | Puromycin是一种抑制 protein synthesis 的氨基糖苷类抗生素。(Puromycin is an aminoglycoside antibiotic that inhibits protein synthesis.) |
靶点 | Bacterial |
通路 | Anti-infection |
生物活性 | Puromycin dihydrochloride是嘌呤霉素的二盐酸盐。 Puromycin是一种抑制 protein synthesis 的氨基糖苷类抗生素。[1-3] |
In Vitro | 嘌呤霉素在氨酰基-sRNA形成后阻断蛋白质合成,同时它导致小肽的积累。这两种效应似乎都是由于核糖体结合的肽基-sRNA的分裂,导致不完整肽链的释放[1]。嘌呤霉素是氨酰基-tRNA的3末端的类似物,通过与生长的多肽链非特异性连接而导致翻译过早终止。嘌呤霉素具有两种抑制作用模式。第一种是通过作为受体底物,其攻击P位点中的肽基-tRNA以形成新生肽。第二种是通过与氨酰基-tRNA竞争结合A位点[2]。当以最小量使用时,嘌呤霉素掺入新合成的蛋白质直接反映体外mRNA翻译的速率。嘌呤霉素免疫检测是放射性氨基酸标记的有利替代方案。它允许通过免疫荧光显微镜直接评估单细胞中的翻译活性,并通过荧光激活细胞分选直接评估异质细胞群[3]。 |
数据来源文献 | [1]. Nathans D, et al. Puromycin inhibition of protein synthesis: incorporation of puromycin intopeptide chains. Proc Natl Acad Sci U S A. 1964 Apr;51:585-92.
[2]. Miyamoto-Sato E, et al. Specific bonding of puromycin to full-length protein at the C-terminus. Nucleic Acids Res. 2000 Mar 1;28(5):1176-82. [3]. Schmidt EK, et al. SUnSET, a nonradioactive method to monitor protein synthesis. Nat Methods. 2009 Apr;6(4):275-7 |
规格 | 5mg 10mM*1mL in Water 10mg 25mg |
Puromycin是一种抑制 protein synthesis 的氨基糖苷类抗生素。
使用本产品的应用案例(仅供参考)
In Vitro
Cell(OC cells,2 μg/mL puromycin)
PCNP expression plasmid and empty vector, the PCNP shRNA (sh-PCNP group) and scramble shRNA (sh-Scb group) and were transfected into OC cells with Lipofectamine 3000 Transfection Reagent to construct stable cell lines. They were screened, respectively, by G418 (Solarbio, Shanghai, China) at a concentration of 800 μg/mL and puromycin (Solarbio, Shanghai, China) at a concentration of 2 μg/mL.
来源文献:Dong P, Fu H, Chen L, Zhang S, Zhang X, Li H, Wu D, Ji X. PCNP promotes ovarian cancer progression by accelerating β-catenin nuclear accumulation and triggering EMT transition. J Cell Mol Med. 2020 Jul;24(14):8221-8235. doi: 10.1111/jcmm.15491. Epub 2020 Jun 16. PMID: 32548978; PMCID: PMC7348179.